Paradigm Biopharmaceuticals share price higher on iPPS update

The Paradigm Biopharmaceuticals Ltd (ASX:PAR) share price climbed 3% on Tuesday after it released an iPPS update…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has pushed higher on Tuesday morning following the release of an update on its knee osteoarthritis study.

The biopharmaceutical company's shares rose 3% to $1.52 in early trade.

What was in the update?

According to the release, Paradigm has treated an additional 22 osteoarthritis patients with injectable pentosan polysulfate (iPPS) under the Therapeutic Goods Administration Special Access Scheme (TGA SAS).

Combining the results of these patients with the previously reported 183 patients, brings the average reduction in pain scores to 51.3% across the 205 patients.

The release goes on to explain that of the 205 patients treated, 89.7% responded with a reduction in joint pain and 91.2% reported an improvement in knee function.

Patient pain scores were reduced by 51.3% and function was improved 58.4% on average from baseline pain scores across the 205 patients with knee osteoarthritis and concurrent bone marrow lesions (BML).

What now?

Management believes the results from these 205 patients provides important real-world evidence (RWE) which has the potential to be used in combination with data from its randomised controlled clinical trials to support regulatory filings with agencies such as the US Food and Drug Administration.

Paul Rennie, Paradigm's chief executive officer said: "We are very pleased to see that since October 2017 and after the report of the eighth group of SAS patients there is a consistent average knee pain reduction of greater than 50% across 205 patients".

He added: "Of important relevance to us is that Paradigm now has accumulated data on 205 patients being successfully treated with iPPS for OA associated BMLs. The number of patients seeking treatment via the TGA SAS is a strong feedback that the patients are receiving a clinically meaningful benefit from the iPPS treatment."

Elsewhere in the industry, the Telix Pharmaceuticals Ltd (ASX: TLX) share price has pushed higher following an update and the CSL Limited (ASX: CSL) share price has edge lower on no news.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

James Mickleboro owns shares of TELIXPHARM DEF SET. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Ecstatic woman looking at her phone outside with her fist pumped.
Share Gainers

Why Catapult, Hutchinson, SKS, and West African shares are pushing higher today

These shares are having a strong session despite the market weakness.

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Gold

Up 72% in 2025, why is this ASX 200 gold stock racing ahead of the benchmark again today?

Investors are bidding up this high-flying ASX 200 gold stock again on Thursday. But why?

Read more »

Businessman smiles with arms outstretched after receiving good news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a wonderful Wednesday session for investors today.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Gold

3 reasons this ASX 200 gold mining giant could soar higher into 2026

A leading expert forecasts more outperformance from this surging ASX 200 gold stock.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Share Gainers

Why Adriatic Metals, Catapult, Seek, and TechnologyOne shares are racing higher today

These shares are having a good time on hump day. But why?

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares returned to positive territory this Tuesday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why Breville, Clarity, EOS, and TechnologyOne shares are racing higher today

These shares are having a strong session on Tuesday. But why?

Read more »

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough start to the week today.

Read more »